Literature DB >> 21288909

Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in cancers.

Yunzhao R Ren1, Kalpesh Patel, Bogdan C Paun, Scott E Kern.   

Abstract

Mesothelin (MSLN) may be the most "dramatic" of the tumor markers, being strongly overexpressed in nearly one-third of human malignancies. The biochemical cause is unclear. We previously ascribed this cancer-specific overexpression to an element, Canscript, residing around 50 bp 5' of the transcription start site in cancer (Hucl, T., Brody, J. R., Gallmeier, E., Iacobuzio-Donahue, C. A., Farrance, I. K., and Kern, S. E. (2007) Cancer Res. 67, 9055-9065). Herein, we found a Canscript promoter activity elevated over 100-fold in cancer cells. In addition to a highly conserved TEAD1 (TEA domain family member 1)-binding MCAT motif, nucleotide substitution revealed the consensus core sequence (WCYCCACCC) of an SP1-like motif in Canscript. The unknown transcription factor binding to the SP1-like motif may hold the key for the cancer specificity of Canscript. SP1, GLI1, and RUNX1, -2, and -3 appeared unlikely to be the direct transcription factors acting at the SP1-like motif, but KLF6 had some features of such a candidate. YAP1, a TEAD1-binding protein, appeared necessary, but not sufficient, for Canscript activity; knockdown of YAP1 by small interfering RNAs greatly reduced MSLN levels in MSLN-overexpressing cells, but overexpressing YAP1 in MSLN-negative cells did not induce MSLN expression. Cansript-like sequences were found in other genes up-regulated in pancreatic cancer; reporters driven by the sequences from FXYD3, MUC1, and TIMP1 had activities more than 2 times that of the control. This suggested that the cause of MSLN overexpression might also contribute mechanistically to the overexpression of other tumor markers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21288909      PMCID: PMC3069398          DOI: 10.1074/jbc.M110.193458

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

Review 1.  Epigenetic gene silencing by Runx proteins.

Authors:  Ichiro Taniuchi; Dan R Littman
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

2.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

Authors:  P Argani; C Iacobuzio-Donahue; B Ryu; C Rosty; M Goggins; R E Wilentz; S R Murugesan; S D Leach; E Jaffee; C J Yeo; J L Cameron; S E Kern; R H Hruban
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

3.  Structure of the Mesothelin/MPF gene and characterization of its promoter.

Authors:  D Urwin; R A Lake
Journal:  Mol Cell Biol Res Commun       Date:  2000-01

4.  TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins.

Authors:  F Kanai; P A Marignani; D Sarbassova; R Yagi; R A Hall; M Donowitz; A Hisaminato; T Fujiwara; Y Ito; L C Cantley; M B Yaffe
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

5.  Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression.

Authors:  Byungwoo Ryu; Jessa Jones; Natalie J Blades; Giovanni Parmigiani; Michael A Hollingsworth; Ralph H Hruban; Scott E Kern
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

6.  Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray.

Authors:  Anirban Maitra; N Volkan Adsay; Pedram Argani; Christine Iacobuzio-Donahue; Angelo De Marzo; John L Cameron; Charles J Yeo; Ralph H Hruban
Journal:  Mod Pathol       Date:  2003-09       Impact factor: 7.842

7.  Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas.

Authors:  Henry F Frierson; Christopher A Moskaluk; Steven M Powell; Hong Zhang; Lisa A Cerilli; Mark H Stoler; Helen Cathro; Garret M Hampton
Journal:  Hum Pathol       Date:  2003-06       Impact factor: 3.466

Review 8.  Mesothelin: a new target for immunotherapy.

Authors:  Raffit Hassan; Tapan Bera; Ira Pastan
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

Review 9.  Sp1- and Krüppel-like transcription factors.

Authors:  Joanna Kaczynski; Tiffany Cook; Raul Urrutia
Journal:  Genome Biol       Date:  2003-02-03       Impact factor: 13.583

10.  Characterization of human mesothelin transcripts in ovarian and pancreatic cancer.

Authors:  Zhanat E Muminova; Theresa V Strong; Denise R Shaw
Journal:  BMC Cancer       Date:  2004-05-12       Impact factor: 4.430

View more
  18 in total

1.  "Selective cell death mediated by small conditional RNAs" is not selective.

Authors:  Kalpesh Patel; Scott E Kern
Journal:  Cancer Biol Ther       Date:  2013-05-31       Impact factor: 4.742

Review 2.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

3.  Unbiased discovery of interactions at a control locus driving expression of the cancer-specific therapeutic and diagnostic target, mesothelin.

Authors:  Yunzhao R Ren; Raghothama Chaerkady; Shaohui Hu; Jun Wan; Jiang Qian; Heng Zhu; Akhilesh Pandey; Scott E Kern
Journal:  J Proteome Res       Date:  2012-10-12       Impact factor: 4.466

Review 4.  Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

Authors:  Raffit Hassan; Anish Thomas; Christine Alewine; Dung T Le; Elizabeth M Jaffee; Ira Pastan
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

Review 5.  Hippo/YAP pathway for targeted therapy.

Authors:  Emanuela Felley-Bosco; Rolf Stahel
Journal:  Transl Lung Cancer Res       Date:  2014-04

Review 6.  A review: hippo signaling pathway promotes tumor invasion and metastasis by regulating target gene expression.

Authors:  Hong-Li Li; Qian-Yu Li; Min-Jie Jin; Chao-Fan Lu; Zhao-Yang Mu; Wei-Yi Xu; Jian Song; Yan Zhang; Sai-Yang Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-17       Impact factor: 4.553

Review 7.  Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.

Authors:  Mark O'Hara; Caitlin Stashwick; Andrew R Haas; Janos L Tanyi
Journal:  Immunotherapy       Date:  2016       Impact factor: 4.196

Review 8.  Discovery of mesothelin and exploiting it as a target for immunotherapy.

Authors:  Ira Pastan; Raffit Hassan
Journal:  Cancer Res       Date:  2014-05-13       Impact factor: 12.701

9.  Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.

Authors:  Zachary W Kendrick; Matthew A Firpo; Robert C Repko; Courtney L Scaife; Douglas G Adler; Kenneth M Boucher; Sean J Mulvihill
Journal:  HPB (Oxford)       Date:  2013-12-06       Impact factor: 3.647

10.  C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma.

Authors:  Futoshi Kawamata; Shigenori Homma; Hirofumi Kamachi; Takahiro Einama; Yasutaka Kato; Masumi Tsuda; Shinya Tanaka; Masahiro Maeda; Kazunori Kajino; Okio Hino; Norihiko Takahashi; Toshiya Kamiyama; Hiroshi Nishihara; Akinobu Taketomi; Satoru Todo
Journal:  J Gastroenterol       Date:  2013-03-20       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.